HCPCS J7639 is officially defined as "Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram." HCPCS J7639 is referenced in 3 tracked payer policy changes from Sentara Health Plans, Indiana Medicaid (IHCP), and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7639 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Indiana Health Coverage Programs (IHCP) is adding coverage for Pulmozyme (dornase alfa) under the medical benefit effective August 1, 2025, using HCPCS code J7639. This inhaled medication for cystic fibrosis will require prior authorization with the same criteria as the existing pharmacy benefit, including age 5+ and prescription by a specialist.
Aetna covers small volume nebulizers and related compressors for listed indications, including antibiotics for cystic fibrosis or bronchiectasis, beta-adrenergics and other inhaled drugs for COPD, dornase alfa for cystic fibrosis or primary ciliary dyskinesia, and epinephrine for croup. Large volume nebulizers are considered medically necessary for pentamidine, bronchiectasis, cystic fibrosis, tracheobronchial stents, and tracheostomy, and ultrasonic nebulizers are considered medically necessary only for tobramycin (Tobi) delivery in members with cystic fibrosis who meet the criteria for a standard nebulizer and the additional criteria in the policy. Aetna considers these nebulizers and related equipment experimental, investigational, or unproven for all other indications, including nebulized corticosteroids for nasal polyps and viral wheezing, nebulized lidocaine, and nebulized magnesium for pediatric asthma.
Watch J7639
Get one email when a payer policy names J7639, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J7639
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J7639 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.